Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with news of another biotech megaround, the potential next big thing from Novo Nordisk, and an anti-aging dispute involving dogs.
VC megarounds still happen
Alumis, a San Francisco biotech firm, has raised $259 million in venture capital to advance its oral anti-inflammatory, bucking some dismal trends in recent fundraising.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect